Acelity, a global advanced wound care and regenerative medicine company, announced today that data from more than 30 abstracts, including 14 oral presentations and 22 poster presentations, will be presented this week at the World Union of Wound Healing Societies (WUWHS) Congress in Florence, Italy (September 25-29).
Featured research includes the use of the PREVENA™ Incision Management System following a variety of surgical procedures, including for patients at risk for complications. The System enables surgeons to apply negative pressure therapy following procedures such as spinal fusion, revision knee and hip replacements and lower extremity trauma fracture. Other studies will examine the impact of V.A.C. VERAFLO™ Therapy and the NANOVA™ Therapy System (not available in the US), a disposable negative pressure wound therapy system, to promote wound healing among patients with acute or chronic wounds, including diabetic foot ulcers that occur in up to 25 percent of people with diabetes.
“Acelity is proud to showcase the data from our extensive wound care portfolio at WUWHS and to demonstrate how our dedication to innovations in medical technology is helping to find more effective healing solutions for patients at every stage of wound care and across all care settings,” said Joe Woody, president and chief executive officer of Acelity. “WUWHS provides an important forum for the global wound care community to discuss clinical concerns, innovation and the future direction of wound care, and we are very honored to share our learnings as a leader in the field.”
WUWHS 2016 marks an important milestone for Acelity. In 2014, the Company united as Acelity, one global company devoted to developing innovative solutions in the areas of advanced wound therapeutics and regenerative medicine. Created by combining the strengths of Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management Limited, together Acelity is committed to advancing the science of healing and restoring people’s lives.
Featured data presentations include:
Tuesday, September 27, Hall Raffaello, 8:00-11:00 a.m., Session 2B
Tuesday, September 27, Poster Gala, Spandolini Pavilion, Upper Floor, Poster Area 6:00-7:00 p.m.
Wednesday, September 28, Hall Renaissance, 8:00-11:00 a.m., Session 3A
Acelity symposia include:
Monday, September 26, Hall Renaissance, 12:15-1:45 p.m.
Advanced Approaches to Complex Clinical Problems in Wound Care
The symposia will feature the highest level of clinical evidence on the latest therapies in wound care for patients with complex wounds. Data surrounding PREVENA™ Incision Management System, V.A.C. VERAFLO™ Therapy and the ABTHERA™ Therapy System are among the topics to be discussed.
Tuesday, September 27, Hall Brunelleschi, 2:00-3:30 p.m.
Achieving Complete Wound Closure with Advanced Modalities
The symposia will focus on the continuum of wound care from wound bed preparation to wound closure, including treatment in the community healthcare setting. Highlighted data include PREVENA™ and CELLUTOME™.
Acelity L.P. Inc. and its subsidiaries are a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. Available in more than 80 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,800 people around the world.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160926005973/en/Business Wire
Last updated on: 26/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.